Eurand Overview
- Year Founded
-
1969
- Status
-
Acquired/Merged
- Employees
-
620
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
3
- Investments
-
2
Eurand General Information
Description
Manufacturer and developer of pharmaceutical and biopharmaceutical products. The company has applied its technologies to drug products in a range of therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition and respiratory.
Contact Information
Formerly Known As
American Home Products (Drug Delivery Business)
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Acquirer
Primary Office
- 123 Olympic Plaza
- Fred. Roeskestraat
- 1076 EE Amsterdam
- Netherlands
+31 020 000 0000
Eurand Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Eurand Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Mario Crovetto | Chief Financial Officer |
Eurand Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Eurand Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Eurand Investments (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| SourceCF | 03-Dec-2007 | 0000000000 | 00.00 | Hospitals/Inpatient Services | 0000000 0 |
| Immunex | 20-May-1999 | Convertible Debt | 00000 | Biotechnology |
Eurand Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Immunex | 20-May-1999 | 00000000000 0000 | 00000 | Completed |
|